Your browser doesn't support javascript.
loading
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley, David M; Matulonis, Ursula A; Birrer, Michael J; Castro, Cesar M; Gilbert, Lucy; Vergote, Ignace; Martin, Lainie P; Mantia-Smaldone, Gina M; Martin, Antonio González; Bratos, Raquel; Penson, Richard T; Malek, Karim; Moore, Kathleen N.
Affiliation
  • O'Malley DM; The Ohio State University, Columbus, OH, United States. Electronic address: David.O'Malley@osumc.edu.
  • Matulonis UA; Dana Farber Cancer Institute, Boston, MA, United States. Electronic address: Ursula_Matulonis@dfci.harvard.edu.
  • Birrer MJ; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, United States. Electronic address: mbirrer@uab.edu.
  • Castro CM; Massachusetts General Hospital, Boston, MA, United States. Electronic address: Castro.Cesar@mgh.harvard.edu.
  • Gilbert L; McGill University Health Centre, Montreal, QC, Canada. Electronic address: lucy.gilbert@mcgill.ca.
  • Vergote I; Leuven Cancer Institute, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be.
  • Martin LP; University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Lainie.Martin@uphs.upenn.edu.
  • Mantia-Smaldone GM; Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address: Gina.Mantia-Smaldone@fccc.edu.
  • Martin AG; Clinica Universidad de Navarra, Madrid, Spain. Electronic address: agonzalezma@unav.es.
  • Bratos R; MD Anderson Cancer Center Madrid, Madrid, Spain. Electronic address: rbratosl@hospiten.com.
  • Penson RT; Massachusetts General Hospital, Boston, MA, United States. Electronic address: Penson.Richard@mgh.harvard.edu.
  • Malek K; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: karim.malek@immunogen.com.
  • Moore KN; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: Kathleen-Moore@ouhsc.edu.
Gynecol Oncol ; 157(2): 379-385, 2020 05.
Article in En | MEDLINE | ID: mdl-32081463
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Ovarian Epithelial Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2020 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Ovarian Epithelial Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2020 Document type: Article Country of publication: United States